Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study

被引:1
|
作者
Suen, Matthew [1 ]
Manski-Nankervis, Jo -Anne [1 ]
McBride, Caroline [1 ]
Lumsden, Natalie [1 ]
Hunter, Barbara [1 ]
机构
[1] Univ Melbourne, Dept Gen Practice & Primary Care, Level 3,North Wing,Bldg,181 Grattan St,Med Bldg, Parkville 3010, Australia
关键词
type; 2; diabetes; CP-FIT; electronic health; clinical decision support tool; primary care; SGLT2; inhibitor; complication; tool; digital health intervention; thematic analysis; decision support; diabetes management; CLINICAL DECISION-SUPPORT; PRIMARY-CARE; MANAGEMENT;
D O I
10.2196/50737
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. Objective: The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. Methods: Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. Results: In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. Conclusions: There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor
    Miwa, Maki
    Nakajima, Mikio
    Kaszynski, Richard H.
    Goto, Hideaki
    BMJ CASE REPORTS, 2020, 13 (10)
  • [2] Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes
    Nisly, Sarah A.
    Kolanczyk, Denise M.
    Walton, Alison M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (04) : 311 - 319
  • [3] Efficacy and Safety of Tofogliflozin on 24-H Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor
    Kurozumi, Akira
    Okada, Yosuke
    Shimokawa, Mototsugu
    Goshima, Yukiko
    Otsuka, Takashi
    Narisawa, Manabu
    Torimoto, Keiichi
    Tanaka, Yoshiya
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (07) : 385 - 392
  • [4] Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
    Shivakumar, Oshini
    Sattar, Naveed
    Wheeler, David C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 43 - 47
  • [5] Empagliflozin: A sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
    Dixit, Divisha
    Yoon, Youngmin
    Volino, Lucio R.
    Mansukhani, Rupal Patel
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (22) : 1943 - 1954
  • [6] Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
    Hedrington, Maka S.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (04) : 613 - 623
  • [7] Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
    Neuen, Brendon L.
    Jardine, Meg J.
    Perkovic, Vlado
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 48 - 55
  • [8] Sodium-glucose cotransporter-2 inhibitor prescribing practices
    Alcorn, Chris
    Subarajan, Prathayini
    Kesari, Aditya
    Lockhart, Marie
    Cottrell, Daryl
    Jordan, Kim
    DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 1136 - 1139
  • [9] Nonclinical Safety of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin
    Bogdanffy, Matthew S.
    Stachlewitz, Robert F.
    van Tongeren, Susan
    Knight, Brian
    Sharp, Dale E.
    Ku, Warren
    Hart, Susan Emeigh
    Blanchard, Kerry
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2014, 33 (06) : 436 - 449
  • [10] Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor
    Koch, Richard A.
    Clark, Richard F.
    AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (05) : E590 - E591